EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSBMUG00000008216
Gene Symbol: EGLN3
3 Cross references
208 Possible Orthologues:

Elastase, Neutrophil Expressed

Ensembl ID : ENSBMUG00000012668
Gene Symbol: ELANE
3 Cross references
91 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSBMUG00000004984
Gene Symbol: EPAS1
3 Cross references
225 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSBMUG00000021756
Gene Symbol: ECE1
3 Cross references
230 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSBMUG00000026595
Gene Symbol: EDNRA
3 Cross references
270 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSBMUG00000008612
Gene Symbol: EDNRB
3 Cross references
267 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSBMUG00000021283
Gene Symbol: EZH2
3 Cross references
235 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSBMUG00000018413
Gene Symbol: LOC102283219
2 Cross references
286 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSBMUG00000014975
Gene Symbol: LOC102269868
2 Cross references
286 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSBMUG00000016915
Gene Symbol: EPHX2
3 Cross references
204 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSBMUG00000002300
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSBMUG00000016997
Gene Symbol: ERBB3
3 Cross references
280 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).